Qinlock and Tenderness - a phase IV clinical study of FDA data

Summary:

Tenderness is reported as a side effect among people who take Qinlock (ripretinib), especially for people who are male, 60+ old, also take Zolpidem, and have Gastrointestinal stromal tumor.

The phase IV clinical study analyzes which people have Tenderness when taking Qinlock. It is created by eHealthMe based on reports of 3,803 people who have side effects when taking Qinlock from the FDA, and is updated regularly.

What is Qinlock?

Qinlock has active ingredients of ripretinib. eHealthMe is studying from 3,803 Qinlock users. Check the latest studies of Qinlock.

What is Tenderness?

Tenderness (pain or discomfort when an affected area is touched) is found to be associated with 1,049 drugs and 1,014 conditions by eHealthMe. Check the latest studies of Tenderness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

3,803 people reported to have side effects when taking Qinlock.
Among them, 13 people (0.34%) have Tenderness.

Among these 13 people:

What is the gender of people who have Tenderness when taking Qinlock? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Tenderness when taking Qinlock? *

What are other drugs people take besides Qinlock? *

What are other side effects people have besides Tenderness? *

Neoplasm Progression (growth of tumour): 6 people, 46.15%
Limb Discomfort (discomfort in leg): 5 people, 38.46%
Muscle Aches (muscle pain): 5 people, 38.46%
Joint Pain: 4 people, 30.77%
Hair Loss: 4 people, 30.77%
Weight Decreased: 3 people, 23.08%
Rashes (redness): 3 people, 23.08%
Pain: 3 people, 23.08%
Stress And Anxiety: 3 people, 23.08%
Hypoaesthesia (reduced sense of touch or sensation): 3 people, 23.08%

What are the existing conditions these people have? *

Gastrointestinal Stromal Tumor: 10 people, 76.92%
Stress And Anxiety: 1 person, 7.69%
Pain In Extremity: 1 person, 7.69%
Pain: 1 person, 7.69%
Osteoporosis (bones weak and more likely to break): 1 person, 7.69%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 7.69%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 7.69%
Drowsiness: 1 person, 7.69%
Diarrhea: 1 person, 7.69%
Depression: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Qinlock and have Tenderness?

- Check whether Tenderness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Qinlock:

Qinlock (3,803 reports)

Tenderness treatments and more:

Tenderness (13,319 reports)

Browse all side effects of Qinlock:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tenderness:

Tenderness (1,049 drugs)

Browse all the conditions that are associated with Tenderness:

Tenderness (1,014 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ripretinib (the active ingredients of Qinlock) and Qinlock (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.